Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Files An 8-K Other EventsItem 8.01. Other Events.
On April18, 2018, Alnylam Pharmaceuticals, Inc. (the “Company”) and Dicerna Pharmaceuticals, Inc. (“Dicerna”) entered into a Settlement Agreement and General Release (the “Agreement”) resolving all ongoing litigation between the companies.
The terms of the Agreement include mutual releases and dismissal with prejudice of all claims and counterclaims in the following litigation between the parties: (i)Alnylam Pharmaceuticals, Inc. v. Dicerna Pharmaceuticals, Inc., No.15-4126, pending in the Massachusetts Superior Court for Middlesex County; and (ii)Dicerna Pharmaceuticals, Inc. v. Alnylam Pharmaceuticals, Inc., No. 1:17-cv-11466, pending in the United States District Court for the District of Massachusetts.
Under the terms of the Agreement, Dicerna will pay to the Company an aggregate of $25.0million, including an upfront cash payment of $2.0million and 983,208 shares of Dicerna common stock, valued at $10.0million, and an additional $13.0million over the next four years, the timing of which will be dependent upon revenue Dicerna receives to future partnerships and collaborations related to Ga1NAc-conjugated RNAi research and development, provided that such additional amount must be paid by no later than April18, 2022. In addition, Dicerna will be restricted in its development and other activities relating to oligonucleotide-based therapeutics directed toward a defined set of Company targets, for periods ranging from 18 months up to four years. The Agreement does not include any license to Company’s GalNAc conjugate intellectual property or any licenses to any other intellectual property from either party. Nor does the Agreement include any admission of liability or wrongdoing by either company.
Item 8.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated April20, 2018.
ALNYLAM PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d575083dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Contacts: Alnylam Pharmaceuticals,…To view the full exhibit click here
About Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its investigational RNAi therapeutics focus on Strategic Therapeutic Areas (STArs), including Genetic Medicines, with a pipeline of RNAi therapeutics for the treatment of diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, such as dyslipidemia, hypertension, non-alcoholic steatohepatitis (NASH) and type II diabetes, and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics for the treatment of hepatic infectious diseases. Its Genetic medicines include Patisiran (ALN-TTR02) and Fitusiran (ALN-AT3), and additional genetic programs, including ALN-AAT.
